Skip to content

Pyrophosphate and Arterial Calcification in Chronic Kidney Disease

Pyrophosphate: a New Biomarker to Predict Arterial Calcification in Chronic Kidney Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04950439
Acronym
Predical
Enrollment
242
Registered
2021-07-06
Start date
2022-03-14
Completion date
2029-03-14
Last updated
2026-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Diseases

Brief summary

Arterial calcifications start at early stages of chronic kidney disease (CKD) and are associated to cardiovascular mortality. Pyrophosphate (PPi) is an endogenous compound, which stops the mineralization process in bones and is expected to act at ectopic sites. In uremic rats, low PPi plasma levels are associated with high calcium content in the aorta and peritoneal administration of PPi blocks this process. People on maintenance dialysis or kidney transplant recipients have low plasma levels of PPi and show high scores of arterial calcification. The purpose is to determine the role of low PPi in the development of arterial calcifications in patients with CKD stage 3 or 4. To that aim, 252 patients with eGFR between 59 et 20 ml/min/1,73 m2 will be recruited and will be examined at baseline and three years later.

Interventions

A blood sample dedicated to the study and necessary for routine care is taken. The pulse wave velocity and systolic pressure index are measured. A myocardial CT scan coupled with a computed tomography is performed. The patient collects stools at his home, simply conditions them and sends them by mail to the centre, which stores them.

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* eGFR between 59 et 20 ml/min/1,73 m2 twice at three month interval

Exclusion criteria

1. kidney transplantation 2. acute inflammatory disease or active cancer

Design outcomes

Primary

MeasureTime frameDescription
Plasma levels of PPI3 yearsTo show that low plasma levels of PPi at baseline is associated with a high progression of arterial calcification at three years after adjustment for confounding variables

Countries

France

Contacts

PRINCIPAL_INVESTIGATORFavre Guillaume, PhD

CHU de Nice, Service de Néphrologie

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 21, 2026